Mark A Behlke
Overview
Explore the profile of Mark A Behlke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
6700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi A, et al.
Sci Adv
. 2020 Nov;
6(47).
PMID: 33208369
Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we describe a safe and efficient lipid...
12.
Kow R, Strovas T, McMillan P, Jacobi A, Behlke M, Saxton A, et al.
Neurobiol Dis
. 2020 Nov;
147:105148.
PMID: 33184027
Aging drives pathological accumulation of proteins such as tau, causing neurodegenerative dementia disorders like Alzheimer's disease. Previously we showed loss of function mutations in the gene encoding the poly(A) RNA...
13.
Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes A, et al.
Blood
. 2020 Sep;
137(5):624-636.
PMID: 32902645
Immune checkpoint therapy has resulted in remarkable improvements in the outcome for certain cancers. To broaden the clinical impact of checkpoint targeting, we devised a strategy that couples targeting of...
14.
Lennox K, Behlke M
Methods Mol Biol
. 2020 Sep;
2176:121-140.
PMID: 32865787
Long noncoding RNAs (lncRNAs) are a recently discovered class of RNA that have diverse intracellular regulatory and structural roles. Because of their wide assortment of functions, lncRNAs can have varied...
15.
Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, et al.
Blood Adv
. 2020 Jul;
4(14):3357-3367.
PMID: 32717029
Virus-specific T cells have proven highly effective for the treatment of severe and drug-refractory infections after hematopoietic stem cell transplant (HSCT). However, the efficacy of these cells is hindered by...
16.
Alharbi A, Garcin A, Lennox K, Pradeloux S, Wong C, Straub S, et al.
Nucleic Acids Res
. 2020 Jun;
48(13):7052-7065.
PMID: 32544249
Oligonucleotide-based therapeutics have become a reality, and are set to transform management of many diseases. Nevertheless, the modulatory activities of these molecules on immune responses remain incompletely defined. Here, we...
17.
Shapiro J, Iancu O, Jacobi A, McNeill M, Turk R, Rettig G, et al.
Mol Ther Methods Clin Dev
. 2020 Jun;
17:1097-1107.
PMID: 32478125
Genome editing of human cluster of differentiation 34 (CD34) hematopoietic stem and progenitor cells (HSPCs) holds great therapeutic potential. This study aimed to optimize on-target, genome editing using the CRISPR-Cas9...
18.
Zhang L, Rube H, Vakulskas C, Behlke M, Bussemaker H, Pufall M
Nucleic Acids Res
. 2020 Apr;
48(9):5037-5053.
PMID: 32315032
CRISPR RNA-guided endonucleases (RGEs) cut or direct activities to specific genomic loci, yet each has off-target activities that are often unpredictable. We developed a pair of simple in vitro assays...
19.
Li W, Chan C, Zeng C, Turk R, Behlke M, Cheng X, et al.
Bioconjug Chem
. 2020 Mar;
31(3):542-546.
PMID: 32119776
CRISPR-Cas12a, a type-V CRISPR-Cas endonuclease, is an effective genome editing platform. To improve the gene editing efficiency of Cas12a, we rationally designed small molecule enhancers through a combined computational approach....
20.
Lennox K, Behlke M
Methods Mol Biol
. 2020 Feb;
2115:23-55.
PMID: 32006393
Chemically modified oligonucleotides (ONs) are routinely used in the laboratory to assess gene function, and clinical advances are rapidly progressing as continual efforts are being made to optimize ON efficacy....